To include your compound in the COVID-19 Resource Center, submit it here.

FDA panel backs Heplisav-B, requests details for postmarketing study

FDA's Vaccines and Related Biological Products Advisory Committee voted 12 to 1, with 3 abstentions, that available safety data support the use of HBV vaccine Heplisav-B from Dynavax Technologies

Read the full 294 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE